Breast cancer remains one of the leading causes of cancer-related mortality among women in Hong Kong, signalling that important gaps in treatment access and support still need to be addressed.

Hong Kong has built significant momentum in early breast cancer (eBC) detection, with more than 70% of breast cancer cases now diagnosed at an early stage. This progress creates a pivotal opportunity to ensure that early detection is matched with timely, guideline-recommended treatment for patients in need.

This position paper explores how Hong Kong can build on this strong foundation by strengthening access to evidence-based treatment for women diagnosed with eBC without delay. While treatment advances such as CDK4/6 inhibitors offer new opportunities to reduce recurrence and improve long-term outcomes, many patients continue to face financial and system-level challenges that limit their ability to benefit from these innovations.

Developed collaboratively by clinical experts and patient groups, the paper highlights practical, consensus-driven strategies for enhancing eBC care. Drawing on global examples from Singapore, Taiwan, and the United Kingdom, it outlines how Hong Kong can align early detection with equitable access to effective treatments through strengthened funding models, streamlined care pathways, and multi-sector partnerships that complement ongoing healthcare reforms.

By acting together, policymakers, clinicians, payers, patient advocates and community organisations can ensure that early diagnosis translates into sustained patient outcomes, improved quality of life, and long-term societal benefits.

Click below to read the full paper and discover how coordinated, evidence-based action can help Hong Kong take the next step in advancing breast cancer care.